NBDF showcases a wide array of findings from the latest in bleeding disorders research at our annual Bleeding Disorders Conference.
Efficacy, safety, and pharmacokinetics of a high-purity plasma-derived factor X (pdFX) concentrate in the prophylaxis of bleeding episodes in children <12 years with moderate to severe congenital factor X deficiency (FXD)
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia A and B with and Without Inhibitors: Interim Results from a Phase 2 Extension Study
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Assessing the Availability and Use of Resources to Support Youth with Hemophilia, their Families and Care Teams during Transition to Adult Health Care
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Collaboration/Team Models
Physician practice patterns in the US show significant variation in how PK parameters are currently used to personalize care for US hemophilia A patients
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Survey Finds Interest in Bleeding Disorder Social Work Specialty Credentialing
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Psychosocial Issues
Impact of targeted education on obesity in children with hemophilia-a single HTC quality project
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Attitudes and Perspectives on Ankle Function in People with Hemophilia: A Qualitative Study
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Orthopedic and Physical Therapy
The WFH Launches World Bleeding Disorders Registry to Expand Knowledge Base Worldwide
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
BAY 94-9027, a Site-Specifically PEGylated Recombinant Factor VIII: Preliminary Results From a Global Comparative Laboratory Field Study
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Lessons Learned From the Assessment and Prevalence of Anxiety and Depression in US Adults With Hemophilia in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study: Importance of Routine Screening and Comprehensive Approaches to Management
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Journey to Best Outcomes in Hemophilia Transition: Passage to Independence
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Collaboration/Team Models
Assessment of numeracy, genetic knowledge and perceptions of genetic testing in carriers of Hemophilia A and B
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Women's Research
Optimal dosing strategies evaluated using a model of the terminal half-life curves for 11 rFVIII products
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Peer Support/Outreach/Integration Models
BAY 81-8973: Safety Observations in Clinical Trials in Adults, Adolescents, and Children With Severe Hemophilia A
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Patient Preferences for FVIII and BAX 855: Results from the BAX 855 Pivotal Trial
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Patients Treated with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Reported Increased or Maintained Physical Activity in the A-LONG and Kids A-LONG Studies
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Hemophilia B Patients Who Switch From rFIX to Extended Half-Life rFIX-Fc: A Retrospective Analysis of Cost using US Specialty Pharmacy Dispensing Data
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Associations Between Annual Bleeding Episodes and Financial Burden of Illness Among Persons with Hemophilia A and B in the United States
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
Increased physical activity levels and improvement in treatment outcomes in patients who switch from on-demand to prophylaxis with BAX 855
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Pegylated full-length recombinant factor VIII (BAX 855) for prophylaxis in previously treated adolescent and adult patients with severe hemophilia A
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials